Norfolk, VA — October 29, 2025 — Synap Biotech welcomed Dr. Pallavi Tawde as Co-Founder and Chief Scientific Officer. Pallavi brings extensive CNS antibody discovery experience from Denali Therapeutics, Bristol Myers Squibb, and Pfizer, strengthening Synap's leadership in next-generation VHH therapeutics.

Norfolk, VA — December 2, 2025 — Synap appointed Professor Serge Muyldermans, pioneer of VHH antibody technology and co-founder of Ablynx, to its Scientific Advisory Board. His expertise provides strategic guidance as Synap advances its neurological recovery platform.

Norfolk, VA — January 6, 2026 — Synap appointed life sciences entrepreneur Brent Buchine, PhD, to its Board of Directors. Brent brings extensive experience in drug delivery, company formation, financing, and commercialization.

Norfolk, VA -April 7, 2026 - Synap Biotech was awarded a $50,000 non-dilutive Launch Grant from the Virginia Innovation Partnership Corporation (VIPC) to accelerate development of its intranasal VHH therapeutic platform.

Norfolk, VA — April 28, 2026 — Synap appointed Dr. Maarten Lansberg, Professor of Neurology at Stanford University and an internationally recognized stroke neurologist, to its Scientific Advisory Board. His expertise in stroke recovery and translational neuroscience strengthens Synap’s development strategy for neurological recovery therapies.

Norfolk, VA - June 24, 2026 - Synap officially launched discovery of its first therapeutic candidates, marking an important milestone in advancing its intranasal VHH platform toward preclinical development